Navan's shares started trading 12% below their initial public offering price on Thursday, as the travel technology company faced choppy market conditions amid a prolonged U.S. government shutdown.

Navan is perhaps the most high-profile IPO over the past month, as the SEC's filing process has stalled with 90% of staff furloughed.

Medline Inc. eyes a $5B IPO to reduce debt amid strong growth in the medical disposables market. Click here to read my latest analysis of MDLN stock.

Medline disclosed on Tuesday that its revenue rose 9.7% in the first half of 2025, as one of the world's largest makers of medical supplies made its IPO filing public ahead of its highly anticipated U.

Navan finished its first day trading at an approximate valuation of $4.7 billion, which is about half of its last private valuation of $9.2 billion.

Inflammation biotech Evommune plans to take the leap into public waters with an expected initial public offering price of $15 to $17 per share. | Inflammation biotech Evommune plans to take the leap into public waters with an expected initial public offering price between $15 and $17 per share.

The challenge - MapLight Therapeutics exists to open possibilities, unlocking new treatments for patients long underserved by

Lenskart IPO shares are expected to be allotted to investors by November 6, while the listing is scheduled to take place on both NSE and BSE on November 10.

On October 30, Studds Accessories Ltd's IPO saw strong demand, with a subscription rate of 1.54 times. The offering seeks to raise ₹455 crore, priced at ₹557-585, closing on November 3. Studds Accessories IPO GMP today is ₹63.